Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated CD20-positive DLBCL confirmed by histopathology or cytology.~* 18 years to 75 years; Male or female patients.~* International Prognostic Index (IPI) score of 0 to 2.~* Signed an informed consent.~* At least one measurable lesions: for nodal tumor mass, more than 1.5 cm in the long axis and more than 1.0 cm in the short axis; for extranodal tumor mass, more than 1.0 cm in the long axis.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.~* More than 6 months life expectancy.~Exclusion Criteria:~* Participation in another interventional clinical trial in the past 3 months.~* Known allergic reactions against monoclonal antibody or rituximab.~* Contraindication to any component of CHOP regimen.~* Previous treatment for DLBCL, including chemotherapy, immunotherapy, partial radiotherapy for lymphoma, or surgical treatment (excluding tumor mass biopsies and surgical resection for non-lymphoma lesions), or prior use of any monoclonal antibody within 3 month.~* History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for other disease (e.g., rheumatoid arthritis).~* Primary central nervous system (CNS) lymphoma, secondary CNS involvement, primary testicular lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBI301 (Type: EXPERIMENTAL): IBI301, 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
- Rituximab (Type: ACTIVE_COMPARATOR): Rituximab,375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).